SOUTH SAN FRANCISCO - Alector, Inc. (NASDAQ: ALEC) reported fourth quarter 2024 results that significantly exceeded analyst expectations, sending shares up 1.7% in after-hours trading.
Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025Anticipate completing enrollment in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback